Physician profile

Peter Cognetti

Family Medicine · Scranton, PA

NPI 1477532208

$926.56

in general payments reported to CMS, 2019-2025

17 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Glaxosmithkline, LLC. $173.72 2019-2020
Novo Nordisk INC $158.66 2019-2020
Horizon Therapeutics Plc $122.17 2019
Amgen INC. $85.47 2019
Astrazeneca Pharmaceuticals LP $70.97 2019
Pfizer INC. $65.99 2019
Boehringer Ingelheim Pharmaceuticals, INC. $38.15 2019
Janssen Pharmaceuticals, INC $37.19 2019
Allergan, INC. $34.31 2020
Astellas Pharma US INC $25.80 2019
Merck Sharp & Dohme LLC $24.11 2019-2020
Genentech USA, INC. $20.58 2019
Novartis Pharmaceuticals Corporation $17.87 2019
Sanofi Pasteur INC. $14.63 2019
Avanir Pharmaceuticals, INC. $14.24 2019
Show all 17 companies
CompanyGeneral paymentsYearsTop products
Teva Pharmaceuticals USA, INC. $11.98 2019
Takeda Pharmaceuticals U.S.A., INC. $10.72 2019

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Peter Cognetti

$926.56

in general payments reported 2019-2025

Years
2019-2020
Top company
Glaxosmithkline, LLC.

https://glasscript.com/doctor/248602/peter-cognetti

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.